Cargando…

Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature

Antithrombin III (AT III) is a plasmatic α-glicoprotein formed by a single peptidic chain. AT III inhibits thrombin (first target) and free Xa, IXa ,VIIa plasmatic factors. In plasma AT III is found under two forms: α-antithrombin and β-antithrombin. Deficiency of AT III represents a risk factor for...

Descripción completa

Detalles Bibliográficos
Autores principales: GĂMAN, AMELIA MARIA, GĂMAN, G.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical University Publishing House Craiova 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340457/
https://www.ncbi.nlm.nih.gov/pubmed/25729597
http://dx.doi.org/10.12865/CHSJ.40.02.12
_version_ 1782359026485428224
author GĂMAN, AMELIA MARIA
GĂMAN, G.D.
author_facet GĂMAN, AMELIA MARIA
GĂMAN, G.D.
author_sort GĂMAN, AMELIA MARIA
collection PubMed
description Antithrombin III (AT III) is a plasmatic α-glicoprotein formed by a single peptidic chain. AT III inhibits thrombin (first target) and free Xa, IXa ,VIIa plasmatic factors. In plasma AT III is found under two forms: α-antithrombin and β-antithrombin. Deficiency of AT III represents a risk factor for thromboembolic disease. There are known both quantitative and qualitative AT III deficiencies. Incidence of AT III inherited deficiency is relative rare (1:10.000). Acquired deficiency of AT III is more frequent. The transmission of AT III deficiency is autosomal dominant with variable shield factor. Homozygous is incompatible with life (death immediately after birth). Thrombosis appears around the age of twenty years, and in 4-5 decades of life 2/3 of patients are symptomatics. Traumatisms, surgical interventions, estrogenic treatment, precipitated thrombotic complications. Obesity and dyslipidemic syndrome are risk factors. Thrombosis affects the venous system at these patients. Arterial thrombosis are less reported. The most frequent localisations are: the veins of the legs, mesenteric veins, cave veins, superficial periombilical veins. Treatment of AT III deficiency is: administration of AT III concentrates (with a plasmatic level by 80% from normal value) and heparinotherapy. The treatment with AT III concentrates is for patients which faced major surgical interventions, pregnant women with AT III deficiency. The women with AT III deficiency should avoid the utilisation of oral contraceptives.
format Online
Article
Text
id pubmed-4340457
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medical University Publishing House Craiova
record_format MEDLINE/PubMed
spelling pubmed-43404572015-02-27 Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature GĂMAN, AMELIA MARIA GĂMAN, G.D. Curr Health Sci J Case Reports Antithrombin III (AT III) is a plasmatic α-glicoprotein formed by a single peptidic chain. AT III inhibits thrombin (first target) and free Xa, IXa ,VIIa plasmatic factors. In plasma AT III is found under two forms: α-antithrombin and β-antithrombin. Deficiency of AT III represents a risk factor for thromboembolic disease. There are known both quantitative and qualitative AT III deficiencies. Incidence of AT III inherited deficiency is relative rare (1:10.000). Acquired deficiency of AT III is more frequent. The transmission of AT III deficiency is autosomal dominant with variable shield factor. Homozygous is incompatible with life (death immediately after birth). Thrombosis appears around the age of twenty years, and in 4-5 decades of life 2/3 of patients are symptomatics. Traumatisms, surgical interventions, estrogenic treatment, precipitated thrombotic complications. Obesity and dyslipidemic syndrome are risk factors. Thrombosis affects the venous system at these patients. Arterial thrombosis are less reported. The most frequent localisations are: the veins of the legs, mesenteric veins, cave veins, superficial periombilical veins. Treatment of AT III deficiency is: administration of AT III concentrates (with a plasmatic level by 80% from normal value) and heparinotherapy. The treatment with AT III concentrates is for patients which faced major surgical interventions, pregnant women with AT III deficiency. The women with AT III deficiency should avoid the utilisation of oral contraceptives. Medical University Publishing House Craiova 2014 2014-03-29 /pmc/articles/PMC4340457/ /pubmed/25729597 http://dx.doi.org/10.12865/CHSJ.40.02.12 Text en Copyright © 2014, Medical University Publishing House Craiova http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
spellingShingle Case Reports
GĂMAN, AMELIA MARIA
GĂMAN, G.D.
Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title_full Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title_fullStr Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title_full_unstemmed Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title_short Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
title_sort deficiency of antithrombin iii (at iii) - case report and review of the literature
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340457/
https://www.ncbi.nlm.nih.gov/pubmed/25729597
http://dx.doi.org/10.12865/CHSJ.40.02.12
work_keys_str_mv AT gamanameliamaria deficiencyofantithrombiniiiatiiicasereportandreviewoftheliterature
AT gamangd deficiencyofantithrombiniiiatiiicasereportandreviewoftheliterature